We value your privacy

This website or its third-party tools process personal data. You can opt out of the sale of your personal information by clicking on the “Do Not Sell or Share My Personal Information” link.

Powered by

Zofran

ACNU Feasibility

View full report
ExcellentOndansetron (oral tablet) has generally mild side effects but requires caution due to QT prolongation risks, drug interactions, and special population considerations. It has low misuse potential, moderate dosing complexity, and needs follow-up to monitor underlying conditions and safety.

ACNU Feasibility Scorecard

Chart with 11 data points.
Zofran
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying ← Lower is Better!. Data ranges from 1 to 5.
End of interactive chart.